Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
RAPT Therapeutics ( (RAPT) ) has provided an update.
On October 21, 2025, RAPT Therapeutics, Inc. announced an underwritten public offering of 8,333,334 shares of its common stock at $30.00 per share, with an option for underwriters to purchase an additional 1,250,000 shares. The company expects to raise approximately $234.4 million, potentially extending to $269.7 million if the option is fully exercised, which will fund operations into 2028. The offering is expected to close on October 23, 2025, subject to customary conditions, and reflects RAPT’s strategic move to secure capital for its ongoing and future projects.
The most recent analyst rating on (RAPT) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on RAPT Therapeutics stock, see the RAPT Stock Forecast page.
Spark’s Take on RAPT Stock
According to Spark, TipRanks’ AI Analyst, RAPT is a Underperform.
RAPT Therapeutics’ overall stock score reflects significant challenges, primarily due to its inability to generate revenue and consistent operational losses. The strong equity position in the balance sheet is a positive, but technical indicators suggest a continued downward trend. The negative valuation metrics further highlight the risks associated with the stock.
To see Spark’s full report on RAPT stock, click here.
More about RAPT Therapeutics
RAPT Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of oral small molecule therapies for oncology and inflammatory diseases.
Average Trading Volume: 287,216
Technical Sentiment Signal: Buy
Current Market Cap: $554.5M
See more data about RAPT stock on TipRanks’ Stock Analysis page.